



TREND ANALYSIS

1Q10 Bioscience VC, M&A and IPO Overview

Key Findings:

- ✓ 74 bioscience venture funded financings raised \$1.26 billion
- ✓ The bioscience public markets continued to thaw welcoming 4 issues
- ✓ 18 biopharma M&A transx >\$100M accounted for \$19.8 billion

Publication Date: 15 April 2010
Report Code: IDOB1003

www.onbiovc.com

Indicium Data
1630A 30th Street
Suite 370
Boulder, CO 80301
USA

t: +1 303 902 4413
e: info@onbiovc.com
twitter @OnBioVC

Information contained herein is based on sources the Company believed reliable at time of reporting but is not guaranteed by the Company or its subsidiaries and is not considered all inclusive, no representation is made to accuracy or completeness, and it should not be relied on as such.

About OnBioVC



The 1Q10 OnBioVC Trend Analysis provides timely coverage and comprehensive analysis of global bioscience private and public capital investment and M&A activity.

This report parses out transactional activity via the tracking of private bioscience companies (including therapeutic, diagnostic, medical device, medical-IT and biofuel sectors) and details bioscience venture investments over time and compares to prior periods. OnBioVC, an Indiciium Data Company, publishes reports quarterly, this report includes data for quarter-over-quarter and year-to-date periods. The venture deal data contained is sorted by aggregate dollars raised via round, region, state and sector, and contains additional information on the indications and technologies receiving investment along with detail on the company who has closed their financing round within the identified time period; this data is followed by an analysis of bioscience public offerings and biopharma M&A deals.

The website OnBioVC.com provides a free and easy to search database where information queries may be indexed by therapeutic, diagnostic, device, medical-IT and biofuel company, technology, indication, financing-round, close date and geographic region — as well as details of the venture capital funds who are financing the deals. All data aggregated at OnBioVC.com is also available for delivery to your inbox via a free email or RSS subscription.

For Advertising Inquiries Contact:

advertise@onbiovc.com

303.902.4413

www.OnBioVC.com

Preclinical ADME Tox Contract Research



Sponsored Article:

The Emerging Role of ADME in Venture Capital

“The most sophisticated VC firms have now begun to grasp how pre-clinical ADME Tox can help them to achieve these objectives. VC firms are increasingly expecting *in vitro* and *in vivo* ADME Tox data not only from the firms they have funded, but also from the ones they are considering funding.”

[Click to Read Article](#)

(or <http://www.apredica.com/articles/EmergingRoleADMEinVC.pdf>)

For more information contact:

Doug Bates, M.S., M.B.A
Chief Business Officer
(781) 679-2172
doug@apredica.com
<http://www.Apredica.com>

“Contract Research at the Pace of Discovery”



Lockton is the world's largest, privately owned, independent insurance broker. With more than 3,800 Associates located WorldWide, Lockton delivers seamless service to companies of all sizes as well as to individual clients.

Lockton has a team in Denver, CO that specializes in the Life Science Industry. They provide all lines of insurance: Casualty, Property, Employee Benefits, Executive Benefits and Retirement Services including the more difficult coverage's of Human Clinical Trials, Products Liability and Directors & Officers Liability.

For more information contact:

Michael Schwander

(303) 414-6122

Mike.Schwander@Lockton.com

<http://Lockton.com>

Insurance, Risk Management & Employee Benefits Specialists



BIOWEST 2010

SAVE THE DATE:

September 29 & 30, 2010

For the Seventh Annual BioWest Conference,
at the Grand Hyatt, Denver

For more information and booth space contact:

Leah Kientz

lkientz@cobioscience.com

(303) 592-4088


<http://BioWestConference.com>

Table of Contents



About ONBioVC	i
1. ONBioVC Trend Analysis	
Executive summary.....	4
Sector representation.....	5
Aggregate dollars raised per round.....	6
Total financings per round.....	7
Aggregate dollars raised per region.....	8
Total financings per region.....	9
Aggregate dollars raised per state.....	10
Total financings per state.....	11
Aggregate dollars and total financings per sector.....	12
Pro forma exit scenario analysis.....	13
Company details.....	14-15
OnBioVC Index™.....	16
2. ONBioIPO Trend Analysis	
IPO watch summary.....	17-19
3. ONBioM&A Trend Analysis	
M&A transactions.....	20

EXECUTIVE SUMMARY



1Q10 Summary Overview

The 1Q10 OnBioVC Trend Analysis tracked, in aggregate, 74 biopharma, diagnostic, device, medical-IT and biofuel venture financings totaling \$1,260.1M. Compared to 1Q09 OnBioVC data — this investment activity represents a decrease in the number of quarter-over-quarter financings by 10 (74 v. 84) and a decrease in quarter-over-quarter invested capital of \$170.0M (\$1,260.1M v. \$1,430.3M).

Perhaps not necessarily emphasized throughout the media, the passage of the health-care reform bill may have impacted the pullback in life science venture investment for 1Q10. There is a bit of a Jekyll and Hyde sentiment associated with the passage of the Bill. Though the notion of universal coverage is lauded by many and undoubtedly expands the market and increases opportunity for the delivery of products, services and procedures there is an equivalent level of concern that tempers the excitement. Specific elements of the Bill around new taxes levied upon medical device manufacturers may ultimately yield a reallocation of finite resources away from innovation, R&D and new product development, or conversely this tax may be packaged such that the cost will be passed on to the consumer. Additional concern is associated with the need to provide comparative-effectiveness studies — though a very sensitive topic there are those investors who believe this could have retarding impact on innovation to do an increase in clinical trial expense. Additional concerns remain around new reimbursement processes.

1Q10 ONBioVC TREND ANALYSIS

COMPAY FOCI	# of Deals	% Total
Device (Dx)	8	10.8%
Device (CV)	5	6.8%
Antibody	4	5.4%
Biologics Mfg.	4	5.4%
Device (Delivery)	4	5.4%
Oncology	4	5.4%
Telemedicine	3	4.1%
Biofuel	2	2.7%
Diabetes	2	2.7%
Inflammation	2	2.7%
Respiratory	2	2.7%
THx Vax	2	2.7%
Vax	2	2.7%
ALD	1	1.4%
Antibiotic	1	1.4%
Autoimmune	1	1.4%
Bioinformatics	1	1.4%
Cirrhosis	1	1.4%
COPD	1	1.4%
CV	1	1.4%
Device (Ablation)	1	1.4%
Device (Bioenergetics)	1	1.4%
Device (COPD)	1	1.4%
Device (Diabetes)	1	1.4%
Device (Orthopedic)	1	1.4%
Device (Renal)	1	1.4%
Device (Sequencing)	1	1.4%
Device (Stent)	1	1.4%
Device (Transplant)	1	1.4%
Device (Ultrasound)	1	1.4%
Device(Dialysis)	1	1.4%
Drug Delivery	1	1.4%
IBS	1	1.4%
Influenza	1	1.4%
Insomnia	1	1.4%
Metabolism	1	1.4%
miRNA	1	1.4%
Neurology	1	1.4%
Obesity	1	1.4%
Pain	1	1.4%
Pancreas	1	1.4%
Reagents	1	1.4%
Wound Healing	1	1.4%
TOTAL	74	100%

Approximately one-in-ten of all venture deals closed in 1Q10 were in the diagnostic space — representing personalized medical approaches leveraging genomics to proteomics to identify certain cancers (e.g. focused on at Aureon Laboratories, Nodality and Saladax Biomedical) to technologies enabling assaying for key informatics on glucose levels, ADHD and the presence of certain viruses. The 1Q10 Dx class raised \$159.4M representing 13% of total dollars invested. The lions share of these dollars were raised by Sunnyvale, CA-based Intuity Medical who closed a \$64M Series D financing. The clinical-stage Company is focused on simplifying diabetes management via their All-in-One™ blood glucose monitoring system. Featured competitive advantages, as communicated by the Company, include an increased level of convenience achieved by the integration of all testing supplies; easy to use one-step testing; &, discretion, where disposing of testing materials is not required.


Investment was also concentrated in the Cardiovascular device space where 5 financings totaled \$89.3M or 7% of quarterly investment dollars. The largest deal of the sector went to Saddle Brook, NJ-based CircuLite who closed a \$32.5M Series C financing. The Company is focused on the treatment of heart failure with the development of a minimally invasive device for long-term partial circulatory support with a 3L/min of flow, designed to increase total cardiac output, offloading the heart and enabling rest and potential beneficial recovery of heart function.

An interesting trend to keep an eye on is the growth in unique biologics manufacturing techniques and technologies. Four companies raised \$39.8M, with one company, PhaseBio Pharmaceuticals who appears to be leveraging their platform for internal THx candidates.


For 1Q10 financings were concentrated in follow-on mid-stage entities. Series B deals lead the way accounting for nearly \$401.2M in capital raised with Series C deals running behind accounting for approximately \$397.3M. The average size rounds for the B increased slightly quarter-over-quarter (\$16.7M v. \$14.4M) while the average size C rounds remained virtually unchanged quarter-over-quarter (\$20.9M v. \$21.1M).

The single largest financing of the quarter was a Series C completed by Reading, UK-based Archimedes Pharma who closed on £65M (\$99M) - perhaps the largest European biopharma deal in at least ten years. The commercial-stage specialty pharma Company's lead product is PecFent®, a fentanyl nasal spray for rapid relief of cancer pain which leverages the Company's proprietary PecSys® delivery technology. PecFent® has successfully completed global Phase III clinical trials and has been filed for regulatory approval in the EU and the US and may be ready for launch in 2010. Other approved products include, for pain, Zomorph and Oramorph; Giladel for high grade glioma; Apomorphine for Parkinson's disease; and Pabrinex, Zibor and Carbimazole for critical care. Along with the financing the Company announced the appointment of a new President and Chief Executive Officer, Jeffrey H. Buchalter, formerly President and Chief Executive Officer of US-based Enzon. Participants in the deal include Novo Growth Equity and Warburg Pincus.

Aggregate Dollars Raised per Round (\$M) 1Q09 v. 1Q10



Total Financings per Round 1Q09 v. 1Q10




	Series A	Series B	Series C	Series D	Series E	Series F	Series G	TOTAL
1Q09 DEALS	26	29	14	9	4	2	-	84
1Q10 DEALS	19	24	19	8	4	-	-	74

1Q10 saw total financings contract relative to 1Q09 by a total of 10 (74 in 1Q10 v. 84 in 1Q09). An interesting trend to observe is the decrease in number of first-time institutional investments, as the Series A round showed a drop by seven deals quarter-over-quarter and this trend is extended to the total Series A dollars invested with a drop of \$94.5M (\$232.9M v. \$327.4M).

Interesting diversity to observe in the late-stage Series E deals where no obvious pattern emerged as demonstrated by Louisville, CO-based GlobelImmune where their \$17.5M is allocated to a late-clinical stage therapeutic vaccine platform with lead candidates in hepatitis C and pancreatic cancer; Regensburg, Germany-based Antisense Pharma similarly picked up \$17.5M to advance their, well, antisense technology in the oncology space; Andover, MA-based TransMedics, a medical device company and developer of a continuous metabolic and functional organ care system for living organ transplants that enables organs to maintain a physiologic functioning state outside of the body, picked up \$36M whose use is intended to expand their commercial presence in the US market; and finally, Mt. Laurel, N.J.-based ImpactRx, who we categorize as Telemedicine sector company, who is developing a mobile platform of treatment data and associated analytics targeted to pharma sales and marketing organizations collected \$1.2M. All in the 1Q10 Series E class accounted for \$72.2M.


Aggregate Dollars Raised per Region (\$M) 1Q09 v. 1Q10



Do you observe anything jump off this histogram? Without any surprise the West region for 1Q10 picked up right where 2009 left off and continued its dominance in attracting bioscience capital investment. With California serving as home to not one but two centers of intellectual property innovation and creation, in San Francisco and San Diego, as well as home to the fund concentration found on Silicon Valley's Sand Hill Road or on Market St. in the Gaslamp; there is something to be said when a CEO may be able to hold a Board of Directors meeting less than an hour away from the home office of their venture investors. No magic or secret sauce is required to build a bio cluster, when the people, IP and money overlap, increased in investment activity transpires and good things tend to emerge. Similarly the concentration of intellectual capital and venture capital converge in the North East in Boston and Cambridge. Thus the North East and West continue to lead in number of deals as total capital attracted.


What is interesting to track are the dollars raised in the second tier regions (i.e. EX-West & North East). The International EX-US region led the way for 1Q10. EX-US 18 deals accounted for \$321.2M and as such represented not only a diverse geographic group (UK, The Netherlands, Israel, South Korea, India, France and Switzerland) but also a diverse group of entities focused on metabolic bone disease, to oncology, inflammation, anti-infectives, autoimmune and CV disease, diagnostics, and devices.

**Total Financings per Region
1Q09 v. 1Q10**



	Ex-US, ROW	Mid Atlantic	Mid West	North East	North West	Rocky Mtn.	South East	South West	West	TOTAL
1Q09 DEALS	20	1	4	24	2	4	3	-	26	84
1Q10 DEALS	18	1	3	26	-	1	4	1	20	74


1Q10 Biopharma Financing Round Frequencies



1Q10 ONBioVC TREND ANALYSIS


FINANCING ROUND	1Q10 DEALS	1Q10 TOT ROUND	1Q10 AVG ROUND	1Q09 DEALS	1Q09 TOT ROUND	1Q09 AVG ROUND
CA	20	423.5	21.2	26	450.4	17.3
CO	1	17.5	17.5	4	60.1	15.0
CT	1	8.5	8.5	2	60.0	30.0
GA	1	20.0	20.0	-	-	-
KY	-	-	-	1	9.0	9.0
LA	-	-	-	1	5.0	5.0
MA	15	258.2	17.2	15	271.0	18.1
MD	1	16.0	16.0	1	10.0	10.0
MI	1	11.0	11.0	1	12.0	12.0
MN	1	9.3	9.3	1	30.0	30.0
MO	-	-	-	1	11.8	11.8
NC	3	39.2	13.1	1	4.0	4.0
NJ	5	69.7	13.9	4	116.5	29.1
NY	2	32.0	16.0	2	30.5	15.3
OR	-	-	-	1	3.0	3.0
PA	2	20.4	10.2	1	10.4	10.4
RI	1	7.0	7.0	-	-	-
TX	1	2.6	2.6	-	-	-
WA	-	-	-	1	7.0	7.0
WI	1	4.0	4.0	1	2.9	2.9
EX-US	18	321.2	17.8	20	336.7	16.8
TOT	74	1,260.1	12.8	84	1,430.3	13.7

**Total Financings per State
1Q09 v. 1Q10**




	CA	CO	CT	GA	KY	LA	MA	MD	MI	MN	MO	NC	NJ	NY	OR	PA	RI	TX	WA	WI	EX-US	TOT
1Q09 DEALS	26	4	2	-	1	1	15	1	1	1	1	1	4	2	1	1	-	-	1	1	20	84
1Q10 DEALS	20	1	1	1	-	-	15	1	1	1	-	3	5	2	-	2	1	1	-	1	18	74

**Total Financings per Sector
1Q09 v. 1Q10**



	Biopharma	Diagnostic	Medical Device	Biofuel	TOTAL
1Q09 DEALS	50	8	23	3	84
1Q10 DEALS	39	8	25	2	74

**Aggregate Dollars Raised per Sector (\$M)
1Q09 v. 1Q10**



	Biopharma	Diagnostic	Medical Device	Biofuel
1Q09 AVG ROUND	19.1	5.5	15.9	22.0
1Q09 TOT ROUND	954.9	44.1	365.2	66.1
1Q10 AVG ROUND	18.4	19.4	14.4	15.0
1Q10 TOT ROUND	715.8	154.9	359.4	30

Pro Forma Exit Scenario Analysis

Value Multiple	% Likelihood	Exit Scenarios	Amt. Invested (\$M)	Exit Value (\$M)
0	43.7%	8	101.8	-
0 to 0.25	8.2%	2	19.1	4.7
0.25 to 0.5	6.8%	1	15.8	7.8
0.5 to 1	8.0%	2	18.6	18.2
1 to 1.5	3.1%	1	7.2	10.6
1.5 to 2	2.3%	0	5.4	10.5
2 to 3	4.1%	1	9.5	28.0
3 to 5	4.7%	1	10.9	53.6
5 to 10	8.6%	2	20.0	196.1
10 to 20	5.1%	1	11.9	232.6
20 to 50	3.8%	1	8.9	433.2
50 to 100	1.1%	0	2.6	250.8
> 100	0.5%	0	1.2	228.0
TOTAL	100%	19	232.9	1,474.0

Here is an interesting look at a pro forma exit scenario analysis for the 1Q10 Series A class of investments. The sophisticated folks at San Hill Econometrics and Professor of Finance Andrew Metrick at the Wharton School of the University of Pennsylvania derived the likelihood of an exit at a particular value multiple. Granted this array is sector agnostic, and not specifically tailored to bioscience investments. But just for fun, what might a potential return on the 19 Series A investments totaling \$232.9M look like at the end of the line?

Certainly there a variety of holes associated with this effort, but if we can speak in generalities it may not be too fantastic a stretch to see that 8 of the 19 investments may end in failure, that is without the return of any capital. An additional 5 failures may return some capital to investors, for example with preference rights and the liquidation of certain assets such as lab and computer equipment or IP, some dollars may be recouped. This now totals 13 or 68% of companies out of the running for a positive return on invested capital. As demonstrated with this data set it is truly the handful of rare 10X+ liquidity opportunities that provide for the requisite returns to raise new funds and the enablement to continue to finance biomedical innovation.


COMPANY	ROUND	RAISE (\$M)	STATE	SECTOR	I° INDICATION
Acton Pharmaceuticals	A	15.0	MA	Biopharma	Respiratory
Advanced Cardiac Therapeutics	A	5.0	CA	Med Device	Device (CV)
Allocade	C	5.0	CA	Med Device	Bioinformatics
Alnara Therapeutics	B	35.0	MA	Biopharma	Pancreas
Antisense Pharma	E	17.5	EX	Biopharma	Oncology
Aquapharm Biodiscovery	C	6.4	EX	Biopharma	Antibiotic
Archimedes Pharma	C	99.0	EX	Biopharma	Pain
Aureon Laboratories	D	7.0	NY	Diagnostic	Device (Dx)
Aurora Biofuels	C	15.0	CA	Biofuel	Biofuel
Bind Biosciences	C	11.0	MA	Biopharma	Oncology
BioBehavioral Diagnostics	B	10.0	MA	Diagnostic	Device (Dx)
Cartcept	B	20.0	GA	Med Device	Device (Delivery)
CeQur	A	29.6	EX	Med Device	Diabetes
Cheetah Medical,	B	20.0	EX	Med Device	Device (CV)
CircuLite	C	32.5	NJ	Med Device	Device (CV)
Direvo	D	8.1	EX	Biopharma	Biologics Mfg.
Elevation Pharmaceuticals	A	30.0	CA	Biopharma	Respiratory
Eleven Biotherapeutics	A	35.0	MA	Biopharma	Inflammation
Eucodis Bioscience	B	2.7	EX	Biopharma	Biologics Mfg.
Excelimmune	B	1.0	MA	Biopharma	Antibody
EyeGate Pharma	D	22.6	MA	Biopharma	Drug Delivery
Flexion Therapeutics	A	9.0	MA	Biopharma	Autoimmune
F-star Biotech	A	10.8	EX	Biopharma	Antibody
Genetix Pharmaceuticals	B	35.0	MA	Biopharma	ALD
Genomatica	C	15.0	CA	Biofuel	Biofuel
Gentical	C	17.7	EX	Biopharma	THx Vax
Glide Pharma	D	4.3	EX	Med Device	Device (Delivery)
Globelimmune	E	17.5	CO	Biopharma	THx Vax
Hemosphere	A	9.3	MN	Med Device	Device(Dialysis)
HistoSonics	A	11.0	MI	Med Device	Device (Ablation)
Immune Targeting Systems	A	13.2	EX	Biopharma	Vax
ImpactRx	E	1.2	NJ	Med Device	Telemedicine
Intercept Pharmaceuticals	B	25.0	NY	Biopharma	Cirrhosis
Intuity Medical	D	64.0	CA	Diagnostic	Device (Dx)
Juvaris BioTherapeutics	B	12.5	CA	Biopharma	Influenza
Kolltan Pharmaceuticals	B	8.5	CT	Biopharma	Antibody
Liquidia Technologies	C	13.0	NC	Med Device	Device (Delivery)
Merus	B	30.7	EX	Biopharma	Antibody
MicroCHIPS	C	16.5	MA	Med Device	Device (Delivery)
NABsys	B	7.0	RI	Med Device	Device (Sequencing)
Nautilus Neurosciences	A	14.5	NJ	Biopharma	Neurology
Navigenics	C	18.0	CA	Diagnostic	Device (Dx)
Neomend	D	30.0	CA	Biopharma	Wound Healing

1Q10 Company List by
State & Investment

1Q10 ONBioVC TREND ANALYSIS

COMPANY	ROUND	RAISE (\$M)	STATE	SECTOR	I° INDICATION
NGM Biopharmaceuticals	B	51.0	CA	Biopharma	Diabetes
Nodality	D	15.5	CA	Diagnostic	Device (Dx)
Omthera Pharmaceuticals	A	6.5	NJ	Biopharma	CV
OriGene Technologies	B	16.0	MD	Biopharma	Reagents
OrthAlign	A	5.2	CA	Med Device	Device (Orthopedic)
Oxford Nanopore Technologies	C	28.0	EX	Diagnostic	Device (Dx)
PatientSafe Solutions	B	30.0	CA	Med Device	Telemedicine
Pearl Therapeutics	C	15.0	CA	Biopharma	COPD
PhaseBio Pharmaceuticals	B	25.0	NC	Biopharma	Biologic Mfg.
PolyTherics	C	4.0	EX	Biopharma	Biologics Mfg.
Promedior	C	12.0	PA	Biopharma	Inflammation
Pulmonx	C	32.0	CA	Med Device	Device (COPD)
Rapid Diagnostek	B	4.0	WI	Diagnostic	Device (Dx)
Reverse Medical	B	14.0	CA	Med Device	Device (CV)
Rhythm Pharmaceuticals	A	10.0	MA	Biopharma	Metabolism
Saladax Biomedical	C	8.4	PA	Diagnostic	Device (Dx)
Seahorse Bioscience	D	5.0	MA	Med Device	Device (Bioenergetics)
Signostics	B	5.0	EX	Med Device	Device (Ultrasound)
Sistemic	A	1.0	EX	Biopharma	miRNA
Somnus Therapeutics	A	15.0	NJ	Biopharma	Insomnia
Syndax Pharmaceuticals	A	9.0	MA	Biopharma	Oncology
Tandem Diabetes Care	C	30.8	CA	Med Device	Device (Diabetes)
TheraSim	A	1.2	NC	Med Device	Telemedicine
Tioga Pharmaceuticals	C	18.0	CA	Biopharma	IBS
Tragara Pharmaceuticals	B	5.0	CA	Biopharma	Oncology
TransMedics	E	36.0	MA	Med Device	Device (Transplant)
TVA Medical	A	2.6	TX	Med Device	Device (Renal)
Valtech Cardio	B	17.8	EX	Med Device	Device (CV)
Vaxart	B	12.5	CA	Biopharma	Vax
Veryan Holdings	B	5.4	EX	Med Device	Device (Stent)
ZafGen	B	8.1	MA	Biopharma	Obesity

ONBIOVC-INDEX™ vs. NASDAQ Biotech Index vs. Dow Jones Industrial Average



Comparing Apples to Bowling-balls:

The OnBioVC-Index™ tracks private bioscience venture investment activity on a relative basis and benchmarks this activity versus the performance of the public markets by charting against the Nasdaq Biotech Index and the broader Dow Jones Industrial Average.

Data Sources: 1) Indiciium Data 2) S&P Index Services 3) BNET Pharma 4) Zack's 5) Yahoo! Finance 6) Fierce Pharma



Whatever the scale or complexity of your project, Regulus has the contacts and the knowledge to maximize your chances of success with regulatory authorities across the world. Our RA team offers expert advice and produces high-quality submissions to meet worldwide regulatory requirements. We have developed strong relationships with the US Food and Drug Administration as well as other regulatory agencies, and regularly represent our customers at critical agency meetings.

Regulatory Affairs - Quality Assurance - Medical/Technical Writing - CMC Regulatory

For more information contact:

Brenda Fielding

(303) 255-0908

bfielding@reguluspharma.com

<http://RegulusPharma.com>

Supporting the Strategic Growth of Your Company

With a Full Spectrum of Regulatory Affairs and Quality Assurance Solutions



Founded in 1998, The Denson Group is an executive search and consulting firm working exclusively in the medical device manufacturing market. Due to our tight focus, we are able to collaborate with startups, early-stage and mid to large-size companies, to assist them in realizing their goals. The Denson Group knows first hand that each hire is a key component to the success of a company.

In the medical device industry, we specialize in Marketing, Sales, Sales Management, and Engineering (development and process) positions at all levels. The majority of our clients find that each need within their organization requires a unique solution. Frequently, we work with a single client under different options simultaneously, depending upon the level of the open positions. We can suggest the appropriate solutions for your specific needs. An advanced comprehensive search and selection process enables us to partner with our client.

The search and selection process flexes to fit individual client requirements, while providing unparalleled levels of service. We understand that our clients not only need a certain skill set, but a mindset and commitment that “gels” with their team. Whether your need is at the CEO level, a Manager, or someone in between, we can help you find that “right fit” talent in a timely manner.

For more information contact:

Steve Denson

(941) 747-4716

steve@densongroup.com

<http://www.DensonGroup.com>

Specialized Services for the Medical Device Industry

The Experience - The Expertise - The Dedication



THE CBSA ADVANTAGE



The BioScience Industry in Colorado

Colorado's bioscience industry is poised to become one of the most exciting and advanced clusters in the country. The State is currently home to a thriving industry, comprised of over 400 biotechnology, medical device, pharmaceutical, health care providers, research institutions and those businesses that provide critical services and products to bioscience companies.

Opportunities for Growth in the Biosciences Industry

The pipeline of new technologies and new companies emerging from Colorado's research institutions is strong; the number of Colorado bioscience related companies and their employees are growing faster than the national average. At the center of this exciting growth is the Colorado Bioscience Association (CBSA), shaping the policies and developing the programs to help Colorado's companies grow and prosper.

**Become a Part of this World Class Bioscience Cluster.
Join the CBSA. For More Information Visit:
www.CoBioScience.com**




ONBioIPO

TREND ANALYSIS

IPO Watch

COMPANY	STATUS	TICKER	SHRS	PRICE	RAISE
Anthera Pharmaceuticals	Out	ANTH	6,000,000	\$ 7.00	\$ 42,000,000
Aveo Pharmaceuticals	Out	AVEO	9,000,000	\$ 9.00	\$ 81,000,000
Ironwood Pharmaceuticals	Out	IRWD	16,700,000	\$ 11.25	\$ 187,875,000
Tengion	Out	TNGN	6,000,000	\$ 5.00	\$ 30,000,000
TOTAL					\$ 340,875,000

The first quarter of the 2010 IPO season picked up where 2009 left off, that is with some growing signs of confidence demonstrated by four new issues and a host of promising filings that should get out in the coming weeks.



IPO Watch (cont'd.)

Ironwood Pharmaceuticals who completed an issuance of 16.7M shrs priced at \$11.25 or total proceeds of approximately \$188M, though the largest IPO of the quarter, in actuality turned out to be a bit of a disappointment as the original pricing, lead by underwriters JP Morgan, Morgan Stanley and Credit Suisse, was thought to come in at \$14-\$16 with a target of \$250M. Despite the underperformance at issuance of some 25%, since its introduction to the Street, Ironwood established a 52 week high of \$15.03.

COMPANY	STATUS	TICKER	SHRS	PRICE	PLAN-RAISE
CorMedix	Filed	CRMD	1,925,000	\$ 6.50	\$ 12,512,500
Neovacs	Filed	N/A	-	\$ -	\$ 20,000,000
Codexis Pharmaceuticals	Filed	N/A	7,357,143	\$ 14.00	\$ 103,000,000
AB Science	Filed	N/A	N/A	N/A	\$ 70,000,000
GenMark Diagnostics	Filed	GNMK	N/A	N/A	\$ 46,000,000
BG Medicine	Filed	N/A	N/A	N/A	\$ 86,300,000
Promethus Labs	Filed	N/A	N/A	N/A	\$ 100,000,000
Chr Hansen	Filed	N/A	N/A	N/A	\$ 1,000,000,000
TOTAL					\$ 1,425,300,000

The capture of near \$4 since issuance has added nearly \$70M in market cap to Ironwood and importantly may be yielding additional confidence for subsequent new deals. The queue appears to be responding accordingly with 8 deals now looking to get out and in the process raise nearly \$1.5B.

Fluidigm and Taminco delayed and canceled their planned public debuts both citing the cause as being related to current market conditions.

IPO Watch (cont'd.)

Some select 1Q10 PIPE financings to note:

Company	Ticker	AMT	SECTOR
Neovasc	NVC	2.0	Device
Solta Medical	SLTM	17.2	Device
Tear Lab	TEAR	3.0	Device
EnteroMedics	ETRM	4.8	Device
Rosetta Genomics	ROSG	5.1	Device
World Heart	WHRT	7.3	Device
Oragenics	ONI	2.5	Biopharma
BioTime	BTIM	2.0	Biopharma
Cyclacel Pharmaceuticals	CYCC	9.5	Biopharma
GenVec	GNVC	26.2	Biopharma
China Pediatric Pharma	LHSI	1.5	Biopharma
Labopharm	DDS	20.0	Biopharma
Pionard Pharmaceuticals	PARD	20.0	Biopharma
Cleveland Biolabs	CBLI	5.0	Biopharma
Dyax	DYAX	17.0	Biopharma
Somaxon Pharmaceuticals	SOMX	49.5	Biopharma
TOTAL		192.6	



ONBIOM&A

TREND ANALYSIS

M&A Watch

ACQUIRER	TARGET	DEAL SIZE (\$M)
Hospira	Orchid Chemicals & Pharma	400
Abbott Labs	Starlims	123
Baxter	ApaTech	330
Teva Pharma	Ratiopharm	4,832
Abbott Labs	Facet	450
Merck KGaA	Millipore	7,200
Cephalon	Ception Therapeutcs	250
Boehringer Ingelheim	SSP	913
Sanofi-Aventis	Chattem	1,900
Cephalon	Mepha	590
BioScrip	Critical Homecare Solutions	343
Martek Bioscience	Amerifit	200
Quidel	Diagnostic Hybrids	130
Medtronic	Invatec	500
Ethicon	Accalarent	785
Thermo Fisher Scientific	Ahura Scientific	145
Merz Pharma	BioForm Medical	253
Stryker	Ascent Healthcare	525
TOTAL		19,869



Freestone provides outsourced business strategy, product development and commercial insight in the life science industry. Our focus is on delivering integrated solutions to address needs associated with building, growing and investing in early and emerging stage life science companies.

Engagements are geared toward increasing capacity in the development and execution of strategies, expansion or extension of operational depth and ultimately, contributing to accelerated milestone achievement and returns. A value-centric focus is utilized to align objectives and dissolve barriers to success.

Our insight and contributions rely on an appropriate foundation of research and analysis to develop and implement business plans. Deliverables provide solutions to business challenges across a range of needs from advisory projects to interim infrastructure support.

Freestone utilizes extensive operational experience to work with organizations to enhance strategies for growth and accelerate the realization of value.

For more information visit:

<http://TheFreestoneGroup.com>

Integrated Solutions for Emerging Life Science



San Jose BioCenter

Accelerating the commercialization of science, the San Jose BioCenter provides a new generation of specialized facilities; capital equipment; laboratory services; and commercialization support for emerging science and technology companies.

The BioCenter is a new, time and cost efficient model to commercialize innovation for emerging science and technology companies. Since inception, the life science and clean technology companies of the BioCenter have raised more than \$1B in capital and have created more than 800 direct jobs.

For more information contact:

Erika Kula
Director, Business Development
(415) 828-1498
erika@sjbiocenter.com
<http://www.SJBioCenter.com>

Giving emerging companies that *Big Company* Advantage...